Physician profile
Keith S Patterson
NPI 1306853874
$9,078.51
in general payments reported to CMS, 2019-2025
47 companies · $2,083 in 2025
The $2,083 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $248 · 2021: $143 · 2022: $1,242 · 2023: $2,055 · 2024: $2,353 · 2025: $2,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,491.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,255.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,073.61 | 2019-2025 | |
| Abbvie INC. | $741.10 | 2022-2025 | |
| Lilly USA, LLC | $661.16 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Corium, LLC | $583.42 | 2022-2025 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $556.54 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $372.11 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $341.75 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.73 | 2019-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $279.15 | 2022 | |
| Abbott Laboratories | $241.29 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $208.74 | 2024-2025 | Caplyta |
| Insulet Corporation | $187.82 | 2024 | Omnipod |
| Astellas Pharma US INC | $185.24 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $155.20 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.